more

Nektar Therapeutics (NKTR)

(Delayed Data from NSDQ)

$1.20 USD

-0.07 (-5.51%)

Updated Aug 2, 2024 04:00 PM ET

After-Market: $1.21 +0.01 (0.83%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.03%
2	Buy	17.70%
3	Hold	9.37%
4	Sell	5.03%
5	Strong Sell	2.48%
S&P	500	11.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth C Momentum F VGM

Industry Rank:

Bottom 39% (154 out of 251)

Industry: Medical - Drugs

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Will Nektar Therapeutics (NKTR) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research Published on May 02,2023

Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks.com featured highlights include Disney, Casey's General Stores, OpGen, Accelerate Diagnostics and Nektar Therapeutics

by Zacks Equity Research Published on April 19,2023

Disney, Casey's General Stores, OpGen, Accelerate Diagnostics and Nektar Therapeutics are part of the Zacks Screen of the Week article.

Nektar (NKTR) Starts New Restructuring Plan to Curb Cash Burn

by Zacks Equity Research Published on April 18,2023

The new restructuring plan will allow Nektar (NKTR) to extend its cash runway into mid-2026. The company plans to reduce its workforce by approximately 60%.

Forget Bargain Hunting, Buy 5 Stocks With Rising P/E

by Sanghamitra Saha Published on April 18,2023

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Disney (DIS), Casey's General Stores (CASY), OpGen (OPGN), Accelerate Diagnostics (AXDX) and Nektar Therapeutics (NKTR).

earnings

Here's Why You May Add Nektar (NKTR) Stock to Your Portfolio

by Zacks Equity Research Published on April 13,2023

Here we discuss some reasons why investing in Nektar Therapeutics (NKTR) stock now is a good idea despite its several pipeline setbacks.

pharmaceuticals

Here's Why You Can Add KalVista (KALV) Stock to Your Portfolio

by Zacks Equity Research Published on April 12,2023

Here we discuss some reasons why investing in KalVista Pharmaceuticals (KALV) stock now is a good idea.

pharmaceuticals

Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce Therapeutics

by Zacks Equity Research Published on April 11,2023

Catalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce Therapeutics are part of the Zacks Industry Outlook article.

medical

5 Stocks to Buy as the Drug Industry Rebounds in 2023

by Kinjel Shah Published on April 10,2023

Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. CPRX, KALV, LRMR, NKTR, JNCE may prove to be good additions to one's portfolio.

biotechs

Why Is Nektar (NKTR) Down 51.9% Since Last Earnings Report?

by Zacks Equity Research Published on March 30,2023

Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

NKTRNegative Net Change

Nektar (NKTR) Upgraded to Buy: Here's Why

by Zacks Equity Research Published on March 24,2023

Nektar (NKTR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

NKTRNegative Net Change

Down -69.13% in 4 Weeks, Here's Why You Should You Buy the Dip in Nektar (NKTR)

by Zacks Equity Research Published on March 22,2023

Nektar (NKTR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

NKTRNegative Net Change

Sage Therapeutics, Inc. (SAGE) Soars 9.6%: Is Further Upside Left in the Stock?

by Zacks Equity Research Published on March 14,2023

Sage Therapeutics, Inc. (SAGE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Relay Therapeutics, Inc. (RLAY) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research Published on February 23,2023

Relay Therapeutics, Inc. (RLAY) delivered earnings and revenue surprises of 21.13% and 66.27%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Concert (CNCE) Moves 19.3% Higher: Will This Strength Last?

by Zacks Equity Research Published on January 09,2023

Concert (CNCE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

by Zacks Equity Research Published on November 11,2022

Smart Beta ETF report for XPH

Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

by Zacks Equity Research Published on November 09,2022

Sector ETF report for XPH

Nektar's (NKTR) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research Published on November 04,2022

Nektar (NKTR) reports encouraging third-quarter 2022 results. The narrower-than-expected loss is on account of lower operating expenses incurred during the quarter.